Circulating CD137(+) T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients

Pembrolizumab, an anti-PD-1 antibody, has been approved as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma ((R/M) HNSCC). However, only a minority of patients benefit from immunotherapy, which highlights the need to identify novel biomarkers to optimize treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Cirillo, Alessio, Zizzari, Ilaria Grazia, Botticelli, Andrea, Strigari, Lidia, Rahimi, Hassan, Scagnoli, Simone, Scirocchi, Fabio, Pernazza, Angelina, Pace, Angelica, Cerbelli, Bruna, d’Amati, Giulia, Marchetti, Paolo, Nuti, Marianna, Rughetti, Aurelia, Napoletano, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138766/
https://www.ncbi.nlm.nih.gov/pubmed/37108276
http://dx.doi.org/10.3390/ijms24087114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138766/
https://www.ncbi.nlm.nih.gov/pubmed/37108276
http://dx.doi.org/10.3390/ijms24087114

Ejemplares similares